Crispr Therapeutics AGKapitalflussrechnung
| Preis (2026-07-24) | 52W Hoch | 52W Tief |
| 46.54 USD | 78,48 USD | 44,12 USD |
| Analysten Konsens | Buy | Outperform | Hold | Underperform | Sell |
| 86,211 USD | 12 | 5 | 10 | 0 | 1 |
| #Shares | Short [%] | Short Ratio |
| 98.484.128 | 22,97 | 11,26 |
Kennzahl in 1000 USD | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|
Umsatz | - | - | - | - | - | - | - | - | - | - | - |
Cashflow aus operativer Geschäftstätigkeit | - | - | - | - | - | - | - | - | - | - | - |
▸ Operative Cashflow Marge | -% | -% | -% | -% | -% | -% | -% | -% | -% | -% | -% |
Investitionsausgaben (CapEx) | - | - | - | - | - | - | - | - | - | - | - |
Cashflow aus Investitionstätigkeit | - | - | - | - | - | - | - | - | - | - | - |
Cashflow aus Finanzierungstätigkeit | - | - | - | - | - | - | - | - | - | - | - |
Freier Cashflow | - | - | - | - | - | - | - | - | - | - | - |
▸ Freie Cashflow Marge | -% | -% | -% | -% | -% | -% | -% | -% | -% | -% | -% |
Ausgeschüttete Dividenden | - | - | - | - | - | - | - | - | - | - | - |
Neuausgabe und Rückkäufe von Stammaktien | - | - | - | - | - | - | - | - | - | - | - |